MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings for MDxHealth SA (MDXH)
Earnings in 2023 (TTM): $-43,099,000
According to MDxHealth SA's latest financial reports the company's current earnings (TTM) are $-43,099,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MDxHealth SA
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-43,099,000 | $-43,100,000 |
| 2022 | $-44,044,000 | $-50,188,000 |
| 2021 | $-29,002,000 | $-30,877,000 |
| 2020 | $-28,662,000 | $-30,007,000 |
| 2019 | $-43,675,000 | $-43,100,000 |
| 2018 | $-32,491,000 | $-32,450,000 |
| 2017 | $-12,401,000 | $-12,288,000 |
| 2016 | $-13,287,000 | $-13,174,000 |
| 2015 | $-14,473,000 | $-14,473,000 |
| 2014 | $-15,256,000 | $-15,256,000 |
| 2013 | $-16,175,000 | $-16,175,000 |
| 2012 | $-11,870,818 | $-11,870,818 |
| 2011 | $-9,003,953 | $-9,003,953 |
| 2010 | $-10,944,275 | $-10,976,194 |
| 2009 | $-20,489,713 | $-20,489,713 |
| 2008 | $-14,188,267 | $-14,188,267 |
| 2007 | $-14,543,572 | $-14,543,572 |
| 2006 | $-9,724,294 | $-9,724,294 |
| 2005 | $-5,071,597 | $-5,071,597 |
| 2004 | $-7,040,993 | $-7,040,993 |